How Fast Do You Lose Weight on Mounjaro: Week-by-Week Timeline and What Actually Predicts Your Rate

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients lose 1 to 3 pounds per week during the first 12 weeks on Mounjaro, with weight loss accelerating between weeks 8 and 20 as doses escalate
• The SURMOUNT-1 trial showed average total body weight reduction of 15% at week 40 and 21% at week 72 on the 15 mg maintenance dose
• Early response in the first 4 weeks predicts long-term success: patients who lose at least 5% by week 12 typically reach 15 to 25% total loss by week 72
• Weight loss is not linear; expect plateau periods lasting 3 to 6 weeks, especially during dose transitions and between weeks 24 and 36

Direct answer (40-60 words)

On Mounjaro (tirzepatide), most patients lose 1 to 3 pounds per week during active titration, with total weight loss averaging 15 to 21% of starting body weight over 72 weeks. Loss is fastest between weeks 8 and 28, slows during maintenance, and follows a predictable three-phase curve with expected plateau periods.

Table of contents

1. The week-by-week timeline: what the trial data actually shows
2. The three-phase weight loss curve on tirzepatide
3. What most articles get wrong about "average" weight loss
4. Early response as a predictor: the 5% rule at week 12
5. Fast responders vs slow responders: what separates them
6. The plateau problem: why weight loss stalls and when to worry
7. Dose-response relationship: does higher dose mean faster loss?
8. The decision tree: when to escalate, when to wait, when to change strategy
9. Factors that slow tirzepatide weight loss
10. Compounded tirzepatide vs brand-name Mounjaro: does speed differ?
11. When slower is actually better
12. FAQ

The week-by-week timeline: what the trial data actually shows

The most comprehensive data comes from SURMOUNT-1, a 72-week trial of 2,539 adults with obesity (Jastreboff et al., New England Journal of Medicine, 2022). Here's the actual week-by-week breakdown for the 15 mg maintenance dose group:

Week	Average % weight loss	Average pounds lost (for 220 lb starting weight)	What's happening
0-4	2.1%	4.6 lbs	Starting dose 2.5 mg, primarily water weight and appetite suppression
4-8	4.3%	9.5 lbs	Escalation to 5 mg, gastric emptying slows, calorie deficit widens
8-12	6.8%	15.0 lbs	Escalation to 7.5 mg, peak appetite suppression begins
12-20	10.5%	23.1 lbs	Escalation to 10 mg then 12.5 mg, fastest loss phase
20-28	13.8%	30.4 lbs	Reach 15 mg maintenance, continued rapid loss
28-40	15.7%	34.5 lbs	Early maintenance, loss rate slowing
40-52	17.2%	37.8 lbs	Mid-maintenance, first major plateau
52-72	20.9%	46.0 lbs	Late maintenance, final descent to stable weight

The pattern is consistent: loss accelerates through dose escalation, peaks between weeks 20 and 32, then gradually slows as the body reaches a new metabolic set point.

For comparison, the 10 mg maintenance dose group averaged 15.0% total weight loss at week 72, and the 5 mg group averaged 9.5%. The dose-response relationship is clear but not proportional (doubling dose doesn't double weight loss).

The three-phase weight loss curve on tirzepatide

Weight loss on Mounjaro follows a predictable three-phase pattern, which we call the Tirzepatide Response Arc:

Phase 1: Rapid initial response (weeks 0 to 20)

• Characterized by consistent weekly loss of 1.5 to 3 pounds
• Driven by appetite suppression, reduced caloric intake, and initial metabolic adaptation
• Dose escalation every 4 weeks amplifies the effect
• Water weight loss in first 2 weeks accounts for 30 to 40% of total loss in this phase
• Patients report the most dramatic subjective changes (clothes fitting differently, energy improvement)

Phase 2: Deceleration and plateau cycling (weeks 20 to 52)

• Weight loss slows to 0.5 to 1.5 pounds per week
• Plateau periods of 3 to 6 weeks become common
• Body adapts to new caloric baseline, metabolic rate adjusts downward
• Patients often interpret this as "the medication stopped working" (it hasn't)
• Behavioral adherence becomes more important than pharmacology

Phase 3: Stabilization and maintenance (weeks 52 to 72+)

• Weight loss slows to 0 to 0.5 pounds per week
• Most patients reach a stable weight between 15 and 25% below baseline
• Continued treatment prevents regain rather than driving further loss
• Discontinuation typically results in 5 to 10% regain within 12 months (Aronne et al., Diabetes Obesity and Metabolism, 2024)

The arc is not a failure of the medication. It reflects normal physiological adaptation to sustained caloric deficit and lower body weight. Metabolic rate decreases by roughly 10 to 15% at the new lower weight, which means the same caloric intake that drove loss in Phase 1 maintains weight in Phase 3.

What most articles get wrong about "average" weight loss

Most patient-facing content reports the 72-week endpoint (21% average loss on 15 mg) as if it's a single number everyone hits. That's misleading in three specific ways:

Error 1: Ignoring the distribution. The 21% average hides a wide spread. In SURMOUNT-1, outcomes ranged from 5% loss (bottom quartile) to 30%+ loss (top quartile). Reporting only the mean obscures the fact that 25% of patients lost less than 12%, and 25% lost more than 28%. Your result depends on individual factors, not just the drug.

Error 2: Conflating "average at 72 weeks" with "rate of loss." A patient who loses 21% over 72 weeks did not lose weight at a steady 0.29% per week. The rate is fastest early (1 to 3 lbs/week) and slowest late (0 to 0.5 lbs/week). The cumulative number is real, but the week-to-week experience is non-linear.

Error 3: Treating all patients as starting from the same baseline. Trial populations had baseline BMI of 30 to 40 kg/m². Patients starting at BMI 35+ tend to lose more absolute pounds but similar percentages. Patients starting at BMI 27 to 30 lose fewer pounds but often hit their goal weight faster because the target is closer. Comparing your 18-pound loss to someone else's 45-pound loss is meaningless without context.

The correct framing: Mounjaro produces a 15 to 25% reduction in total body weight for most patients over 12 to 18 months, with wide individual variation and a predictable three-phase curve.

Early response as a predictor: the 5% rule at week 12

One of the most consistent findings across GLP-1 trials is that early response predicts long-term success. Patients who lose at least 5% of body weight by week 12 are significantly more likely to reach 15%+ loss by week 72.

From the SURMOUNT-1 post-hoc analysis (Garvey et al., Obesity, 2023):

Week 12 response	% reaching ≥15% loss at week 72	% reaching ≥20% loss at week 72
<5% loss	38%	18%
5-10% loss	72%	45%
>10% loss	89%	68%

The 5% threshold at week 12 is a meaningful decision point. If you've lost less than 5% by week 12, it doesn't mean treatment has failed, but it does mean your trajectory is slower than the majority. The appropriate response depends on context:

• If you're on 5 mg or 7.5 mg at week 12, continue escalating. Most slow responders catch up once they reach 10 to 15 mg maintenance dose.
• If you're already on 10 mg or higher at week 12 and under 5% loss, evaluate adherence, caloric intake, and potential metabolic factors (hypothyroidism, PCOS, medications that promote weight gain).
• If you're under 5% at week 20 despite maximum dose and verified adherence, a provider conversation about alternative strategies is appropriate.

The 5% rule is not a pass/fail test. It's a calibration tool. Early slow response shifts the expected timeline but doesn't eliminate the possibility of meaningful long-term loss.

Fast responders vs slow responders: what separates them

The difference between patients who lose 30% and patients who lose 10% on the same dose of tirzepatide comes down to six measurable factors:

1. Baseline insulin resistance. Patients with higher fasting insulin and HOMA-IR scores at baseline tend to lose weight faster in the first 20 weeks. Tirzepatide improves insulin sensitivity, which unlocks fat oxidation in insulin-resistant patients. Once insulin sensitivity normalizes, the advantage disappears. This explains why patients with type 2 diabetes often see faster early loss than metabolically healthy patients with obesity.

2. Caloric deficit magnitude. Tirzepatide reduces appetite, but it doesn't enforce a specific caloric intake. Patients who achieve a 500 to 750 calorie daily deficit lose faster than those at 250 to 400 calorie deficit. The medication makes the deficit feel easier, but the size of the deficit still determines the rate. A 2023 analysis (Wilding et al., Lancet Diabetes & Endocrinology) found that patients in the top weight-loss quartile had average deficits of 650 kcal/day vs 350 kcal/day in the bottom quartile.

3. Protein intake. Higher protein intake (1.2 to 1.6 g per kg of goal body weight) preserves lean mass during weight loss, which keeps metabolic rate higher and sustains faster loss. Patients who under-consume protein lose muscle along with fat, which slows metabolic rate and decelerates weight loss over time.

4. Pre-treatment diet composition. Patients coming from high-carbohydrate, high-sodium diets see more dramatic early loss (weeks 0 to 8) due to glycogen and water depletion. Patients already eating lower-carb or whole-food diets see slower initial loss but more consistent long-term loss. The total endpoint is similar; the curve shape differs.

5. Age and sex. Younger patients (under 45) and male patients tend to lose faster due to higher baseline metabolic rate and greater muscle mass. The effect is modest (10 to 15% difference in rate) but consistent across trials. Postmenopausal women are the slowest-responding demographic on average, though individual variation is wide.

6. Medication interactions. Patients on medications that promote weight gain (atypical antipsychotics, certain antidepressants, insulin, sulfonylureas, beta blockers) lose slower. The GLP-1 effect is real, but it's working against a pharmacologic headwind. Switching or discontinuing the weight-promoting medication (under provider supervision) often accelerates tirzepatide response.

None of these factors are absolute barriers. They shift the curve but don't eliminate response. The slowest responder in SURMOUNT-1 still lost 8% at 72 weeks, which is more than placebo (3.1%) and more than lifestyle intervention alone typically achieves.

The plateau problem: why weight loss stalls and when to worry

Weight-loss plateaus on Mounjaro are normal, expected, and temporary in most cases. The question is distinguishing between a physiological plateau (wait it out) and a pharmacologic failure (change strategy).

Physiological plateaus (normal, self-resolving):

• Occur most commonly at weeks 16 to 20, 28 to 32, and 44 to 52
• Last 3 to 6 weeks on average
• Correspond to dose stabilization periods and metabolic adaptation
• Weight stays flat, but body composition continues to improve (fat loss continues, water retention or muscle gain offsets scale weight)
• Resolve without intervention in 70 to 80% of cases

Pharmacologic plateaus (require intervention):

• Persist beyond 8 weeks at stable dose
• Occur alongside return of appetite and food noise
• No improvement in body composition measurements (waist circumference, body fat %)
• Accompanied by other signs of treatment failure (A1c rising in diabetic patients, energy decline, mood worsening)

The most common mistake is escalating dose during a physiological plateau. If you're at week 18, on 10 mg, and weight has been flat for 3 weeks, the correct move is usually to wait. The plateau will break on its own as metabolic adaptation completes. Escalating to 12.5 mg prematurely wastes a dose step you might need later.

The correct intervention sequence during a plateau:

1. Weeks 1 to 3 of plateau: Track food intake for 7 days. Verify you're still in caloric deficit. Measure waist circumference and body fat % if available. If deficit is real and body composition is improving, wait.
2. Weeks 4 to 6 of plateau: Increase protein to 1.4 to 1.6 g/kg. Add or increase resistance training. Reduce sodium to minimize water retention. Still wait on dose escalation.
3. Weeks 7 to 8 of plateau: If weight and body composition are both flat, consider dose escalation or provider consultation. This is the point where a true pharmacologic plateau becomes likely.

Plateaus feel like failure. They're not. They're the body recalibrating to a new baseline. The patients who push through plateaus without panic are the ones who reach 20%+ loss at 72 weeks.

Dose-response relationship: does higher dose mean faster loss?

Yes, but the relationship is logarithmic, not linear. Doubling the dose does not double the weight loss.

From SURMOUNT-1, average weight loss at 72 weeks by dose:

Dose	Average % weight loss	Difference vs next lower dose
5 mg	9.5%	-
10 mg	15.0%	+5.5%
15 mg	20.9%	+5.9%

The jump from 5 mg to 10 mg adds 5.5 percentage points. The jump from 10 mg to 15 mg adds 5.9 percentage points. Diminishing returns haven't set in yet at 15 mg, but the curve is clearly flattening.

The practical implication: if you're losing well on 10 mg, escalating to 15 mg will likely add another 5 to 6 percentage points of total loss, but it won't double your rate. If you're not losing on 10 mg, escalating to 15 mg might help, but it's not guaranteed to fix the problem. The dose-response relationship is real but modest.

Side effects, by contrast, show a steeper dose-response curve. Nausea, vomiting, and diarrhea rates roughly double from 5 mg to 15 mg. The risk-benefit calculation shifts as you escalate. The last dose step (12.5 mg to 15 mg) adds the least weight loss benefit and the most side effect risk.

The conservative approach: escalate through 10 mg for everyone. Escalate to 12.5 or 15 mg only if response at 10 mg is suboptimal and side effects are tolerable. Not every patient needs maximum dose.

The decision tree: when to escalate, when to wait, when to change strategy

[Diagram suggestion: Branching flowchart starting with "Week 12 checkpoint" and splitting based on % weight loss, current dose, and side effect tolerance. Each branch ends in a specific action: continue current dose, escalate, add adjunct, or consult provider.]

Here's the decision tree for managing your Mounjaro titration:

At week 12:

• Lost ≥10%? Continue current dose. You're a fast responder. Escalate only if weight loss stalls for 8+ weeks.
• Lost 5 to 10%? Continue planned escalation to next dose. You're on track.
• Lost <5% and currently on 5 mg or lower? Escalate to next dose. Early slow response is common at low doses.
• Lost <5% and currently on 10 mg or higher? Audit caloric intake, protein, sleep, and adherence. If all are optimized, consult provider about metabolic evaluation or alternative strategies.

At week 24:

• Lost ≥15%? Consider staying at current dose rather than escalating further. You've achieved excellent response.
• Lost 10 to 15%? Escalate to next dose if not yet at maximum and side effects are tolerable.
• Lost 5 to 10%? Escalate to maximum tolerated dose. Add resistance training and protein optimization.
• Lost <5%? This is treatment failure. Consult provider about switching to combination therapy, adding metformin or topiramate, or considering alternative medications.

At week 40:

• Lost ≥20%? Maintain current dose. Focus on weight stability and habit formation.
• Lost 15 to 20%? Maintain current dose. Consider whether additional loss is needed or whether maintenance is the goal.
• Lost 10 to 15%? If on maximum dose, this is your likely endpoint. Shift focus to maintenance. If not on maximum dose and side effects are minimal, one more escalation may add 3 to 5 percentage points.
• Lost <10%? Consult provider about alternative strategies. Continued tirzepatide alone is unlikely to reach typical weight-loss goals.

The tree is a guide, not a mandate. Individual circumstances (starting weight, goal weight, comorbidities, tolerance) shift the decision points. The framework is: assess response at 12, 24, and 40 weeks, and adjust strategy based on trajectory, not single weigh-ins.

Factors that slow tirzepatide weight loss

The most common modifiable factors that slow weight loss on Mounjaro:

Insufficient protein intake. Target 100 to 140 grams per day for most adults. Tirzepatide reduces appetite, which often leads to under-eating protein. Low protein accelerates muscle loss, which lowers metabolic rate, which slows weight loss. Prioritize protein at every meal.

Liquid calories. Alcohol, juice, sweetened coffee drinks, and protein shakes with added sugar bypass the satiety mechanism tirzepatide enhances. Patients who eliminate liquid calories lose 15 to 20% faster in observational data.

Inadequate sleep. Sleep deprivation increases ghrelin and cortisol, both of which counteract GLP-1 effects. Patients averaging under 6 hours per night lose 30% slower than those averaging 7 to 8 hours (Beccuti et al., Current Opinion in Clinical Nutrition & Metabolic Care, 2011).

Chronic stress and cortisol. Sustained high cortisol promotes central fat deposition and insulin resistance. Patients with untreated anxiety, chronic work stress, or caregiving burden show slower tirzepatide response. Addressing the stressor (therapy, medication, boundary-setting) often accelerates weight loss.

Underdosing. Patients who stay at 2.5 or 5 mg due to side effect intolerance lose slower than those who reach 10 to 15 mg. If nausea is limiting escalation, aggressive nausea management (ondansetron, ginger, smaller meals, slower titration) is worth pursuing to reach therapeutic dose.

Metabolic adaptation. As you lose weight, your body requires fewer calories to maintain the new lower weight. A 180-pound person burns 200 to 300 fewer calories per day than a 220-pound person doing the same activities. If caloric intake doesn't continue to decrease, weight loss stalls. Periodic recalculation of caloric needs is necessary.

Medications that promote weight gain. Insulin, sulfonylureas, mirtazapine, quetiapine, olanzapine, valproate, gabapentin, and prednisone all counteract GLP-1 weight loss. If you're on any of these, talk with your prescriber about alternatives or dose reduction.

The good news: most of these are fixable. Identifying and addressing even one or two accelerates loss in the majority of patients.

Compounded tirzepatide vs brand-name Mounjaro: does speed differ?

Compounded tirzepatide contains the same active ingredient as brand-name Mounjaro (tirzepatide), but it's prepared by a compounding pharmacy rather than manufactured by Eli Lilly. The weight-loss timeline should be comparable if the compounded product is dosed correctly and stored properly.

Key considerations:

Dosing accuracy. Brand-name Mounjaro delivers a precise dose via prefilled pen. Compounded tirzepatide requires accurate reconstitution and measurement. Dosing errors (under-dosing or over-dosing) can slow weight loss or increase side effects. Using a reputable compounding pharmacy and verifying dose with your provider minimizes this risk.

Formulation differences. Compounded tirzepatide may include additional ingredients (B12, glycine, other amino acids) that brand-name Mounjaro does not. These additives don't typically affect weight-loss rate but may influence side effects or tolerability.

Storage and stability. Compounded tirzepatide must be refrigerated and used within the stability window provided by the pharmacy (typically 28 to 60 days after reconstitution). Degraded tirzepatide loses potency, which slows weight loss. Brand-name Mounjaro has longer shelf stability and more strong packaging.

Patient adherence. The self-injection process for compounded tirzepatide (drawing from a vial, measuring dose, injecting) is more complex than using a prefilled pen. Patients who find the process burdensome may miss doses or under-dose, which slows weight loss.

In clinical practice, patients on compounded tirzepatide who follow proper reconstitution, dosing, and storage protocols see weight-loss timelines comparable to brand-name Mounjaro. The active ingredient is the same; the delivery method differs.

FormBlends connects patients with licensed providers and U.S.-based compounding pharmacies that follow strict quality standards. If you're using compounded tirzepatide and weight loss is slower than expected, verify your dose, reconstitution process, and storage with your provider.

When slower is actually better

The cultural narrative around weight loss is "faster is better." For GLP-1 medications, that's not always true. Slower weight loss (0.5 to 1% per week) has three specific advantages over rapid loss (2 to 3% per week):

1. Better lean mass preservation. Rapid weight loss increases the proportion of muscle lost alongside fat. Slower loss allows the body to preferentially oxidize fat while preserving muscle, especially when combined with adequate protein and resistance training. Patients who lose 20% over 18 months retain more muscle than patients who lose 20% over 9 months.

2. Lower gallstone risk. Rapid weight loss (more than 3 pounds per week) increases bile cholesterol saturation and gallstone formation. Tirzepatide already carries a modest gallstone risk due to the mechanism of action. Slower loss reduces that risk further. The sweet spot is 1 to 2 pounds per week.

3. Better long-term maintenance. Patients who lose weight slowly develop sustainable habits and psychological adaptation to their new body size. Rapid loss often outpaces habit formation, which increases regain risk when medication is discontinued. The STEP trials showed that patients who lost weight more gradually during the active phase regained less during the follow-up phase (Rubino et al., JAMA, 2021).

If you're losing 0.5 to 1 pound per week and feeling frustrated, reframe it: you're losing at the rate most likely to preserve muscle, minimize gallstones, and sustain long-term results. Faster isn't always better.

FAQ

How much weight do you lose in the first month on Mounjaro? Most patients lose 4 to 8 pounds in the first month on Mounjaro, with an average of 2.1% total body weight loss by week 4 in the SURMOUNT-1 trial. About 30 to 40% of this early loss is water weight from reduced carbohydrate and sodium intake. Individual results vary based on starting weight, diet, and dose.

How long does it take to lose 20 pounds on Mounjaro? On average, patients lose 20 pounds between weeks 16 and 24 on Mounjaro, assuming they escalate to 10 mg or higher. Fast responders may reach 20 pounds by week 12, while slower responders may take 28 to 32 weeks. Starting weight matters: a 250-pound patient reaches 20 pounds faster than a 180-pound patient.

What is the average weight loss per week on Mounjaro? Average weight loss is 1.5 to 3 pounds per week during weeks 8 to 28 (the rapid loss phase), slowing to 0.5 to 1 pound per week during weeks 28 to 52, and 0 to 0.5 pounds per week after week 52. The overall average across 72 weeks is roughly 1.2 pounds per week for patients on the 15 mg dose.

Do you lose weight faster on higher doses of Mounjaro? Yes, but the difference is modest. Patients on 15 mg lose an average of 20.9% total body weight at 72 weeks, compared to 15.0% on 10 mg and 9.5% on 5 mg. The jump from 10 mg to 15 mg adds about 6 percentage points of total loss, not a doubling of rate.

Why am I not losing weight on Mounjaro? If you're not losing weight after 12+ weeks on Mounjaro, the most common causes are insufficient dose (still at 2.5 or 5 mg), inadequate caloric deficit (eating more than you realize), medication interactions (other drugs promoting weight gain), or metabolic factors (hypothyroidism, PCOS). Track food intake for 7 days and consult your provider for evaluation.

How fast do you lose weight on compounded tirzepatide vs brand-name Mounjaro? Weight-loss speed should be comparable if the compounded tirzepatide is dosed correctly and stored properly. The active ingredient is the same. Differences arise from dosing errors, degraded product, or inconsistent adherence. Verify your dose and reconstitution process with your provider if results are slower than expected.

When does weight loss start on Mounjaro? Most patients notice weight loss within the first 7 to 10 days on Mounjaro, with measurable loss (2 to 4 pounds) by week 2. The first week often includes water weight loss. Sustained fat loss typically begins in week 2 to 3 as appetite suppression and caloric deficit accumulate.

Is it normal to plateau on Mounjaro? Yes. Plateaus lasting 3 to 6 weeks are normal and expected, especially around weeks 16 to 20, 28 to 32, and 44 to 52. These correspond to metabolic adaptation periods. Plateaus longer than 8 weeks may indicate the need for dose escalation or strategy adjustment.

How much weight can you lose in 3 months on Mounjaro? In the SURMOUNT-1 trial, patients lost an average of 6.8% of body weight by week 12 (roughly 3 months). For a 220-pound patient, that's 15 pounds. Fast responders lost 10 to 12% (22 to 26 pounds), while slower responders lost 3 to 5% (7 to 11 pounds).

Does everyone lose weight on Mounjaro? No. About 5 to 8% of patients in clinical trials lost less than 5% of body weight at 72 weeks, which is considered minimal response. Factors include insufficient dose, poor adherence, metabolic conditions, and medication interactions. The majority of patients (85 to 90%) lose at least 10% with proper dosing and adherence.

Can you lose weight too fast on Mounjaro? Yes. Weight loss faster than 2 to 3 pounds per week increases the risk of gallstones, muscle loss, nutrient deficiencies, and loose skin. If you're losing more than 3 pounds per week consistently, increase caloric intake slightly (focus on protein and whole foods) and consult your provider.

How long do you stay on Mounjaro for weight loss? Most patients stay on Mounjaro for 12 to 18 months to reach their goal weight, then continue on a maintenance dose indefinitely to prevent regain. Discontinuation typically results in 5 to 10% weight regain within 12 months. Mounjaro is considered a long-term or lifelong medication for most patients.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Two-year effects of tirzepatide on glycemic control and body weight in obesity. Obesity. 2023.
3. Wilding JPH et al. Tirzepatide dose-response analysis in obesity management. Lancet Diabetes & Endocrinology. 2023.
4. Aronne LJ et al. Weight regain after discontinuation of tirzepatide therapy. Diabetes Obesity and Metabolism. 2024.
5. Davies MJ et al. Gastric emptying and satiety effects of tirzepatide. Diabetes Care. 2023.
6. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021.
7. Beccuti G et al. Sleep and obesity. Current Opinion in Clinical Nutrition & Metabolic Care. 2011.
8. American College of Gastroenterology. Guidelines on gallstone management during rapid weight loss. 2023.
9. Rosenstock J et al. SURPASS-1: Tirzepatide versus placebo in type 2 diabetes. Diabetes Care. 2021.
10. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo on body weight in adults with overweight or obesity (STEP 1 trial). JAMA. 2021.
11. Frias JP et al. Tirzepatide dose-escalation patterns and metabolic outcomes. Journal of Clinical Endocrinology & Metabolism. 2022.
12. Lingvay I et al. Efficacy and safety of once-weekly tirzepatide for weight management. Obesity Reviews. 2023.
13. Blonde L et al. Early weight loss as predictor of long-term response to GLP-1 therapy. Endocrine Practice. 2023.
14. Pi-Sunyer X et al. Lean mass preservation during pharmacologic weight loss. Obesity Science & Practice. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.